Prenuvo

Market position

Prenuvo is a prominent player in consumer preventative whole-body MRI screening; CNBC describes it as having grown quickly, being profitable, and holding what its CEO calls the largest whole-body MRI image repository in the world. Ezra is identified as a competing full-body MRI startup, which raised $21 million in February 2024.

Prenuvo emphasizes the technical density of its imaging: it says it acquires more voxels at diagnostic-quality signal-to-noise ratio within a 50-minute study, uses up to five times more imaging weightings to help differentiate benign from concerning lesions and reduce false positives, and includes extensive diffusion-weighted imaging. It also cites human radiologist interpretation of every report, standardized protocols, an in-house research program (50+ publications and studies, with abstracts presented at ISMRM and the American Academy of Neurology), and, per its CEO, the largest repository of whole-body MRI imaging in the world, which it intends to use to train models that improve accuracy and radiologist efficiency.

Technology

A multi-sequence, non-contrast, radiation-free MRI protocol run on open-bore machines (70 cm bore, 550 lb table limit) that produce high-resolution voxel data with extensive diffusion-weighted imaging and up to five times more tissue weightings than comparison approaches. Layered on top are AI components: an FDA-cleared body composition algorithm measuring fat distribution, organ volumes and lower-body muscle volume/symmetry; NeuroQuant FDA-cleared AI brain analysis; and MyoStrain-based cardiac function analysis in select clinics. The company also runs AI-assisted research on its imaging repository, including studies of brain effects of exercise, smoking and alcohol and AI-based analysis of the female reproductive system, and builds proprietary tooling connecting MRI findings with lab data.

Go-to-market

Prenuvo markets directly to health-conscious consumers through its website, patient testimonials, gift cards, promotional discounts, published research and press coverage, with awareness aided by celebrity users and investors. It converts single-scan buyers into annual memberships positioned around longitudinal tracking. New assessments are rolled out first at flagship locations (Silicon Valley, Los Angeles, New York) before wider availability. A CNBC video reference indicates a collaboration with insurer John Hancock on longevity.

Health-conscious adults paying out of pocket for proactive screening: first-time screeners seeking a baseline, people who already prioritize health and want more data points, and consumers focused on longevity and health optimization who value tracking data over time.

Geography

As of February 2025 the company owned and operated 17 clinics across North America, with plans to add 15 more locations including sites in Europe and Australia. Pricing pages reference U.S. clinics in New York City, Los Angeles, Chicago, Atlanta, Boca Raton, Bethesda, Scottsdale, Houston, San Diego, Denver, Seattle, Minneapolis, Dallas, Miami, Pasadena, Irvine and Las Vegas, plus Silicon Valley; CAD pricing is listed for Canada, and job listings reference Vancouver, British Columbia.

History

Prenuvo's site states the company is backed by venture capital firms and individual investors in health, fitness and consumer brands, including Felicis Ventures, 23andMe CEO Anne Wojcicki, Nest founder Tony Fadell, Eric Schmidt, Cindy Crawford, Dr. Timothy A. Springer and Casamigos co-founder Rande Gerber. In February 2025 the company announced a $120 million round co-led by Left Lane Capital, Forerunner Ventures and existing investor Felicis, alongside the launch of blood testing, a brain health scan and an FDA-cleared AI body composition product. At that time it reported 17 owned-and-operated clinics in North America, more than 110,000 members and $100 million of 2024 revenue, with plans for 15 additional locations including Europe and Australia.

Risks & controversies

Prenuvo has been criticized for its high prices, and some medical experts warn that its scans are not a substitute for targeted screening and may prompt patients to pursue unnecessary follow-up care. The company itself documents extensive scan limitations and notes that nearly all patients show some imaging abnormalities or incidental findings, many of which are age- or lifestyle-related and not immediately actionable. Scans are unavailable or restricted for certain patients (pacemakers, pregnancy, some implants, size/weight limits). Blood panels are available only at eligible U.S. clinic locations and some products only at select clinics. A CNBC correction notes the company misstated that it had developed the neurological sequence technology, which in fact comes from a partner.